The researchers wrote, "Further research is warranted to identify subroups that benefit from beta blocker
therapy and the optimal duration of beta blocker
Washington, May 14 ( ANI ): Contrary to current thinking, researchers of new study have found that taking beta blockers
that treat high blood pressure does not decrease a person's risk of developing colorectal cancer.
Never stop taking your beta blocker
or any other heart medication without your doctor's approval.
In the 123 patients taking beta blockers
, only 9 percent of the serious arrhythmias occurred on Mondays.
Our findings revealed that differences in beta blocker
survival benefit observed in clinical trials may be significantly influenced by inclusion of varying geographic populations.
The clear benefits of beta blocker
use in cardiovascular disease are well known but their use is generally avoided in patients who also have COPD, because of concerns they might cause adverse effects with breathing," the Scotsman quoted Prof Brian Lipworth, who heads the group, as saying.
, such as atenolol (Tenormin), metoprolol (Lopressor, Toprol-XL) and propranolol (Inderal, Inderal LA), certainly have their place in the fight to lower blood pressure--just not on the front lines.
In the recent study, he and Bright looked for a link between long-term beta blocker
use and depression.
Most patients in the clinical trial supporting effectiveness, referred to as A-HeFT, received, in addition to BiDil or placebo, a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker
, and many also received a cardiac glycoside or an aldosterone antagonist.
Such drugs include beta blockers
and angiotensin-converting-enzyme (ACE) inhibitors.
In the OPTIC Study, amiodarone plus beta blocker
significantly reduced appropriate, inappropriate and total number of shocks by suppressing ventricular tachycardia, sinus tachycardia and supraventricular arrhythmias.
ESC guidelines recommend ACE-inhibitors as the first-line therapy in patients with heart failure and a beta blocker
if patients remain symptomatic.
Two of these developmental programs, Bisochron (bisoprolol), a beta blocker
for the treatment of hypertension, and Isochron (isosorbide-5-mononitrate), a long acting nitrate for the treatment of angina, are designed to offer better protection against the increased risk of cardiovascular events caused by the early morning surge in blood pressure.
use for coronary artery disease increased slowly, from 19 percent in 1990 to 20 percent in 1995, and then to 40 percent in 2002.
European data suggest a very low incidence of side effects, particularly fatigue, sexual dysfunction, and headache, which are so often seen with beta blocker